Intellectual Property India Publishes Patent Application for 'Nucleocapsid Antigen Immunotherapy For Covid-19 Fusion Proteins And Methods Of Use' Filed by Vakston, Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517090834 A) filed by Vakston, Inc., Beverly, U.S.A., on Sept. 23, for 'nucleocapsid antigen immunotherapy for covid-19 fusion proteins and methods of use.'

Inventor(s) include Zion, Todd C.; and Lancaster, Thomas M.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the admin...